Transcriptome of Uropathogenic *Escherichia coli* during Urinary Tract Infection

Jennifer A. Snyder,[1] Brian J. Haugen,[2] Eric L. Buckles,[3] C. Virginia Lockatell,[3]
David E. Johnson,[3,4] Michael S. Donnenberg,[3] Rodney A. Welch,[2]
and Harry L. T. Mobley[1]*

*Department of Microbiology and Immunology,[1] Division of Infectious Diseases,[3] University of Maryland School of
Medicine, and Department of Veterans Affairs,[4] Baltimore, Maryland, and Department of Medical
Microbiology and Immunology, University of Wisconsin—Madison, Madison, Wisconsin[2]*

A uropathogenic *Escherichia coli* strain CFT073-specific DNA microarray that includes each open reading frame was used to analyze the transcriptome of CFT073 bacteria isolated directly from the urine of infected CBA/J mice. The in vivo expression profiles were compared to that of *E. coli* CFT073 grown statically to exponential phase in rich medium, revealing the strategies this pathogen uses in vivo for colonization, growth, and survival in the urinary tract environment. The most highly expressed genes overall in vivo encoded translational machinery, indicating that the bacteria were in a rapid growth state despite specific nutrient limitations. Expression of type 1 fimbriae, a virulence factor involved in adherence, was highly upregulated in vivo. Five iron acquisition systems were all highly upregulated during urinary tract infection, as were genes responsible for capsular polysaccharide and lipopolysaccharide synthesis, drug resistance, and microcin secretion. Surprisingly, other fimbrial genes, such as *pap* and *foc/sfa*, and genes involved in motility and chemotaxis were downregulated in vivo. *E. coli* CFT073 grown in human urine resulted in the upregulation of iron acquisition, capsule, and microcin secretion genes, thus partially mimicking growth in vivo. On the basis of gene expression levels, the urinary tract appears to be nitrogen and iron limiting, of high osmolarity, and of moderate oxygenation. This study represents the first assessment of any *E. coli* pathotype's transcriptome in vivo and provides specific insights into the mechanisms necessary for urinary tract pathogenesis.

Urinary tract infections (UTIs) are a serious health concern. Forty to 50% of women experience at least one UTI, leading to an estimated 8 million annual physician visits in the United States alone (39, 46). Uropathogenic *Escherichia coli* (UPEC) is by far the most common etiological agent of all UTIs. UPEC strain CFT073, derived from the clonal group O6:K2:H1 (26), was originally isolated from the blood and urine of a woman diagnosed with acute pyelonephritis (28). It is considered a prototype of the O6 serogroup, one of the most prevalent UPEC clonal lines (23, 24). The virulence of this strain was reproduced in the well-established CBA mouse model of ascending UTI (28). In addition to numerous virulence studies, the genome of *E. coli* CFT073 has recently been sequenced and compared to that of enterohemorrhagic *E. coli* EDL933 and the nonpathogenic laboratory strain *E. coli* MG1655 (42).

Mutations have been introduced into a number of candidate virulence genes in UPEC, leading to attenuated mutants in experimental UTI. These include *fim*, encoding type 1 fimbria (7, 13), *sat*, encoding secreted autotransporter toxin (14), *cnf-1*, encoding cytotoxic necrotizing factor (36), *tonB*, involved in iron transport (40), *proP*, involved in osmoprotectant transport (8), and *degS* (35). Large-scale screens for virulence factors of UPEC have also identified factors that aid UPEC during growth in urine (38) and have implicated capsule, lipopolysaccharide, iron acquisition systems, and the PhoU regulatory system in virulence (3, 35). Molecular Koch's postulates have been satisfied for type 1 fimbriae, DegS, and TonB (9).

In this report, we have quantified the gene expression for each open reading frame (ORF) of this uropathogen from organisms isolated directly from the urine of experimentally infected CBA/J mice. We have identified multiple virulence and metabolic factors that were upregulated to aid survival in the host. We also defined specific environmental conditions that appear to confront *E. coli* CFT073 during experimental UTI.

MATERIALS AND METHODS

Bacterial strains and culture conditions. For in vitro RNA preparation, UPEC strain CFT073 (28) was grown statically at 37°C in 100 ml of Luria broth (LB) until the optical density at 600 nm (OD_{600}) reached 0.65. For RNA preparation from urine, this strain was grown statically at 37°C in 900 ml of pooled human urine until the OD_{600} reached 0.135 (mid-exponential phase for growth in urine). Urine was collected from healthy women volunteers aged 20 to 40 who had no history of UTI or antibiotic use in the prior 2 months. Each urine sample was immediately filter sterilized (0.2 μm pore size) and frozen at −80°C for use within 2 weeks. For each experimental replicate, a different pool of urine samples from three to five volunteers was used. The study was approved by the Institutional Review Board of the University of Maryland School of Medicine. LB- and urine-grown cultures were immediately treated with RNA Protect Bacterial Reagent (QIAGEN) to stabilize RNA according to the manufacturer's instructions and was harvested by centrifugation (8 min, 7,500 × *g*, 25°C). The bacterial pellet was frozen at −20°C until RNA extraction.

CBA/J mouse model of ascending UTI. To establish a relevant source of in vivo-grown bacteria, 40 CBA/J mice were transurethrally inoculated as previously described (15, 21) with 5×10^9 CFU of *E. coli* CFT073. The infection was monitored daily by pooling urine from 10 mice at random and spiral plating on Luria agar to quantify CFU. Mice were reinoculated after 6 days to maintain

infection at levels between 2×10^6 and 3×10^7 CFU/ml of urine, which allowed the collection of sufficient numbers of bacteria needed for RNA extraction and subsequent analysis. Urine was collected for 10 days, with the exception of the first 24 h following the inoculations. On average, 50 μl of urine was collected from each mouse every 45 min during an 8-h period. Urine was collected directly into 1.5-ml microcentrifuge tubes containing 650 μl of RNA Protect Bacterial Reagent (QIAGEN) and was pooled until the total volume reached approximately 1 ml. The RNA Protect-treated sample remained on ice until all samples had been collected for that day. A crystalline precipitate was allowed to settle before pipetting off the bacteria-containing supernatant into a 15-ml centrifuge tube for collection. Tubes were centrifuged (15 min, $2,500 \times g$, 4°C), the supernatant was decanted, and the bacterial pellet was frozen at −20°C until RNA extraction.

RNA isolation and cDNA synthesis. RNA from both in vitro and in vivo samples was extracted using an RNeasy Mini kit with a 1-h on-column DNase digestion (QIAGEN) according to the RNeasy Mini handbook. Multiple RNA preparations of the same sample were pooled prior to cDNA synthesis. Up to 10 μg of RNA was mixed with 750 ng of random hexamers (Invitrogen) for each cDNA synthesis reaction according to a previously described protocol (37). SuperScript II reverse transcriptase (1,500 U; Invitrogen) was added to these reactions, along with First Strand buffer, dithiothreitol, and deoxyribonucleotides at concentrations recommended by the manufacturer (Invitrogen). The reactions were incubated at 25°C for 10 min, 37°C for 60 min, 42°C for 60 min, and 70°C for 10 min. Following RNaseH (Invitrogen) and RNaseA (Ambion) digestion, cDNA was purified with a QIAquick PCR Purification kit (QIAGEN) according to the QIAquick Spin handbook.

Quantitative real-time reverse transcription-PCR (qRT-PCR). Primers designed to amplify *papA_2* of *E. coli* CFT073 were 5′GTGCCTGCAGAAAATG CAGAT and 5′CCCGTTTTCCACTCGAATCA, and primers for *gapA* were 5′CATCGTTTCCAACGCATCCT and 5′ACCTTCGATGATGCCGAAGTT (forward and reverse primers, respectively). Thirty nanograms of cDNA and 300 nM (final concentration) each primer were mixed with 12.5 μl of 2× SYBR Green PCR Master Mix (ABI). Assays were performed in triplicate with the ABI Prism model 7900 instrument. All data were normalized to the internal standard *gapA* (encoding glyceraldehyde 3-phosphate dehydrogenase), and melting curve analysis demonstrated that the accumulation of SYBR Green-bound DNA was gene specific. The $2^{-\Delta\Delta CT}$ method (25) was used for analysis, and the data were transformed by $\log_2$ to obtain a fold change difference between growth conditions.

Microarrays and hybridization. The *E. coli* CFT073-specific DNA microarray (NimbleGen Systems, Inc.) includes 5,611 ORFs and stable RNAs from version 17 of the compiled CFT073 genome sequence. Each ORF is represented on the glass slide by 17 unique probe pairs of 24-mer in situ-synthesized oligonucleotides. Each pair consists of a sequence perfectly matched to the ORF, and another adjacent sequence harbors two mismatched bases for determination of background and cross-hybridization. For each microarray, 3 to 5 μg of cDNA was fragmented using RQ1 DNaseI (Promega) partial digest and was then labeled with biotin-N6-ddATP (Perkin-Elmer Life Sciences) using terminal transferase (Roche) as described previously (37). Labeled cDNA samples were individually hybridized in triplicate to the CFT073-specific microarray according to the NimbleGen standard operating procedure. Following washes and labeling with a streptavidin-Cy3 complex according to the NimbleGen procedure, microarrays were scanned at 5-μm resolution using a GenePix 4000b scanner.

Data and statistical analysis. For LB and in vivo microarrays, data were extracted using NimbleScan (NimbleGen) and an algorithm (courtesy of Yu Qiu, University of Wisconsin School of Medicine) applied to obtain a single measurement of signal intensity for each ORF. Data were normalized and converted to estimates of transcript abundance, using the total signal intensity to allow comparison of individual microarrays (1). A second set of LB-grown microarrays were processed along with the urine-grown microarray, where hybridization and normalization of the microarray were carried out by NimbleGen Systems, Inc. The signal intensity of an ORF was calculated by subtracting the mismatch probe intensity from the perfect match probe intensity for each of the 17 probe pairs, obtaining a mean difference value (excluding values greater than 3.0 standard deviations from the means). These urine- and LB-grown microarrays were normalized with the quantile normalization method and were analyzed with the RMA algorithm (6, 20). For all microarrays, a *P* value for each ORF was calculated by a two-tailed Welch's unpaired *t* test comparison of the three microarray replicates for each bacterial growth condition. Fold changes of an ORF between growth conditions were calculated by transformation of the following ratio: $\log_2$ [(average in vivo-grown or urine-grown signal intensity)/(average LB-grown signal intensity)]. Only fold changes of at least ±2 and $P \leq 0.05$ were considered significant and are discussed in this report. Thus, ORFs characterized as upregulated (fold change, ≥2; $P \leq 0.05$) or downregulated (fold change, ≤−2; $P \leq$ 0.05) during growth in vivo or during growth in urine are relative to growth in LB.

RESULTS

Alterations in the transcriptome of *E. coli* CFT073 during UTI. To further understand the mechanisms UPEC employ in UTIs, we used *E. coli* CFT073-specific DNA microarrays to analyze the transcriptome of this strain grown under both in vivo and in vitro conditions. The source for in vivo-grown bacteria was the urine from infected mice, collected from 1 to 10 days postinoculation for use in RNA isolation. The sources for in vitro-grown RNA were cultures of *E. coli* CFT073 grown statically to mid-exponential phase at 37°C in either LB or filtered human urine. The expression level of each of 5,611 ORFs was determined for each condition. An ORF was considered differentially regulated if the statistically significant change in expression was also greater than twofold. All in vivo- and urine-derived data are described here relative to growth in LB.

Overall, 313 genes were found upregulated (Table 1 lists the 50 most upregulated), and 207 genes were downregulated during growth in vivo. To identify candidate virulence genes specific to *E. coli* CFT073 that may play a role during UTI, all 313 genes upregulated in vivo were evaluated for the absence or presence of a homologue in the *E. coli* K-12 nonpathogenic strain (Table 1). This analysis revealed 45 genes that were not found in *E. coli* K-12 and 41 genes encoding hypothetical proteins that were unable to be confidently categorized. Of these 45 candidate virulence genes, 25 genes previously implicated in virulence encoded iron acquisition, capsule synthesis, or microcin secretion proteins and 13 encoded hypothetical proteins.

By comparison to UPEC CFT073 grown in LB, bacteria coming from the urinary tract have upregulated expression of virulence and metabolic factors in the host (Fig. 1). Not only were a variety of factors upregulated, but these genes were presumably translated at a rapid rate. Thirty-five of the 50 most highly expressed genes in vivo encoded translational machinery (Table 2).

Adhesins. Colonization is a major challenge facing UPEC in the urinary tract. Thus, adherence factors that aid in this process are essential to survival. The genome sequence of *E. coli* CFT073 revealed an abundance of fimbrial adhesins relative to levels in both enterohemorrhagic and nonpathogenic laboratory *E. coli* strains. Indeed, as many as 12 fimbrial gene clusters have been predicted or demonstrated (4, 21, 42). Our in vivo microarray data revealed that the *fim* genes encoding type 1 fimbriae were preferentially expressed 12 to 72 times more highly than each of the 11 other fimbrial gene clusters. Additionally, *fimA*, encoding the major structural subunit, was the fourth most highly expressed gene in vivo overall; the first three were related to translation. *fim* genes were the only genes previously implicated as virulence factors among the 50 most highly expressed genes in vivo (Table 2). The 11 remaining fimbrial gene clusters were minimally expressed, if at all.

Not only were type 1 fimbriae highly expressed, but they were also highly upregulated (three- to fivefold) (Fig. 2) compared to levels for the LB culture grown statically, conditions known to enhance type 1 fimbrial production (33). Both of the *pap* gene clusters of strain CFT073 encoding P fimbriae were downregulated two- to fourfold, and the *foc/sfa* gene cluster and *sfaB* recombinase of F1C fimbriae were also downregulated two- to fivefold. The *csg* genes, which encode thin aggregative curli fibers, were downregulated two- to fourfold in vivo.

TABLE 1. Top 50 genes upregulated in vivo during UTI

Gene	Function	Fold change[a]	*P* value
rspA	Repression of stationary-phase gene sigma-S	6.021	0.0059
sitA[b]	Iron transport system SitA protein	5.634	<0.0001
c1903	Unknown	5.556	0.0018
rspB	Repression of stationary-phase gene sigma-S	5.532	<0.0001
entE	Enterobactin synthetase component E (enterochelin)	5.482	0.0032
chuW[b]	Putative coproporphyrinogen III oxidase; hemin utilization	5.417	0.0016
yhjX	Putative drug resistance protein YhjX	5.416	0.0312
iucA[b]	Aerobactin protein IucA	5.166	0.0025
proV	Glycine betaine/L-proline transport ATP-binding protein ProV	5.150	0.0025
entA	Enterobactin system dehydrogenase	5.115	0.0113
entF	Enterobactin synthetase component F	5.012	0.0134
uxuB	D-mannonate oxidoreductase	4.982	0.0049
srlD	Sorbitol-6-phosphate 2-dehydrogenase	4.912	0.0055
uxuA	Mannonate dehydratase	4.740	0.0026
tyrA	T protein	4.643	0.0002
fdnI	Formate dehydrogenase, nitrate inducible	4.623	0.0066
deaD	Cold-shock DEAD-box protein A	4.614	0.0024
nirD	Nitrite reductase [NAD(P)H] small subunit	4.601	0.0022
yeaR	Hypothetical protein YeaR	4.579	0.0018
lpxB	Lipid-A-disaccharide synthase	4.570	0.0006
fimC	Type 1 fimbriae; chaperone protein FimC precursor	4.553	<0.0001
c1905[b]	Hypothetical protein	4.552	0.0081
c5174[b]	Putative iron-regulated outer membrane virulence protein	4.539	0.0024
c1220	Phospho-2-dehydro-3-deoxyheptonate aldolase, Trp sensitive	4.529	0.0013
yhfI	Hypothetical oxidoreductase YdfI	4.523	0.0065
iroN[b]	Siderophore receptor IroN	4.491	0.0207
dut	Deoxyuridine 5′-triphosphate nucleotidohydrolase	4.488	0.0163
chuS[b]	Putative heme/hemoglobin transport protein; hemin utilization	4.473	0.0128
iroB[b]	Putative glucosyltransferase; siderophore system	4.466	0.0056
iucD[b]	Aerobactin protein IucD	4.433	0.0009
sitB[b]	Iron transport system SitB protein	4.404	0.0020
yncE	Hypothetical protein YncE precursor	4.341	0.0058
rplI	50S ribosomal protein L9	4.318	0.0122
c4088	Hypothetical protein	4.271	0.0142
yoaG	Hypothetical protein YoaG	4.268	<0.0001
c3610[b]	Putative receptor	4.242	0.0113
c0672	Conserved hypothetical protein	4.234	0.0030
c2203	Hypothetical protein	4.218	0.0001
kpsE[b]	Capsule biosynthesis KpsE protein	4.127	0.0126
entC	Isochorismate synthase EntC, enterobactin system	4.108	0.0011
srlE	PTS system, glucitol/sorbitol-specific IIBC component	4.096	0.0002
rnpA	Ribonuclease P protein component	4.094	0.0122
fimF	Type 1 fimbriae; FimF protein precursor	4.084	0.0001
gidA	Glucose inhibited division protein A	4.052	0.0021
marR	Multiple antibiotic resistance protein MarR	4.038	0.0002
hmpA	Flavohemoprotein (hemoglobin-like protein)	3.993	0.0148
glnP	Glutamine transport system permease protein GlnP	3.992	0.0016
c4090	Hypothetical protein	3.966	0.0225
srlB	PTS system, glucitol/sorbitol-specific IIA component	3.956	0.0012
chuT[b]	Putative periplasmic binding protein; hemin utilization	3.956	0.0270

[a] Fold change refers to growth in vivo relative to growth in LB.
[b] This gene was not present in *E. coli* K-12.

The *flu* gene, encoding antigen 43 and implicated in autoaggregation and biofilm formation, was also downregulated twofold in vivo (Fig. 2). Besides type 1 fimbriae, only one other adhesion-related gene (*ydeS*, encoding a hypothetical fimbria-like structural protein) was upregulated during UTI.

Iron acquisition systems. Iron is essential for growth of *E. coli*, and five iron uptake and assimilation systems were upregulated during bacterial growth in the urinary tract. Siderophore systems were upregulated in vivo two- to fivefold, providing evidence that the urinary tract is an iron-limiting environment (31). These systems include *ent* genes encoding enterobactin, *iuc* genes encoding aerobactin, and *iro* genes encoding an *ent*-like system. Additionally, *iutA*, *exbD*, *fhuA*, *fhuC*, and the *fep* genes, all involved in the transport of these ferrisiderophore complexes; the *chu* genes, required for hemin utilization; and *sit* genes, encoding an iron transport system, were upregulated two- to fivefold (Fig. 3). The expression of *tonB*, necessary for iron and siderophore uptake, remained unchanged between in vivo and LB growth.

Motility. *E. coli* CFT073 is motile, as is characteristic of the species. There has been speculation that flagella assist UPEC in the ascent from the bladder to the kidneys through the ureters (29). The role of flagella in colonization is unknown, but epidemiological data indicate that nonmotile strains may be overrepresented among UTI isolates (10, 16). Our in vivo microarray data demonstrated that several genes involved in flagellation were downregulated in comparison to these genes during LB growth (Table 3), including *flgL* and *flgK*, class III genes encoding hook-filament flagellar structural components, and *cheW*, encoding a positive regulator of chemotaxis. Importantly, the *fliC* gene, encoding flagellin, was downregulated fivefold. Although not meeting statistical criteria, all 11 remaining class III flagellar and chemotaxis genes demonstrated a trend toward downregulation in vivo. Overall, these data do not support a primary role for motility during infection of the urinary tract.

Capsule and LPS. Capsular polysaccharide and lipopolysaccharide (LPS) O side chains may be involved in UPEC virulence, perhaps by conferring resistance to serum and phagocytosis (18). These microarray data confirmed the importance of extracellular polysaccharides. The genes *kpsE*, *kpsD*, *kpsC*, and *kpsS*, involved in the transport of polysaccharide to the cell surface, were upregulated two- to fourfold during infection. *lpxA* and *lpxB*, both involved in lipid A biosynthesis, were


FIG. 1. Functional categories of differentially expressed *E. coli* CFT073 genes. The number of genes that are significantly upregulated (black bars) or downregulated (grey bars) during growth in vivo (growth during UTI) relative to growth in static LB culture are categorized based on function.

TABLE 2. Top 50 genes expressed by *E. coli* CFT073 in vivo during UTI

Gene	Function	Signal intensity	Fold change[a]	*P* value	Among top 50 in urine[c]	Among top 50 in LB[c]
tufB	Protein chain elongation factor EF-Tu	34.27	1.02	0.015	+	+
rpsK	30S ribosomal subunit protein S11	33.99	1.15	<0.001	+	+
rplE	50S ribosomal subunit protein L5	32.91	1.73	0.004	+	
fimA[b]	**Major type 1 fimbrial subunit; fimbrin/pilin**	**32.75**	**2.97**	**0.009**		
rpsS	**30S ribosomal subunit protein S19**	**31.58**	**2.31**	**0.003**		
rplX	50S ribosomal subunit protein L24	31.27	1.71	<0.001	+	
rpsE	30S ribosomal subunit protein S5	29.86	1.93	<0.001	+	
rpsN	30S ribosomal subunit protein S14	29.28	1.65	0.006	+	
rplR	50S ribosomal subunit protein L18	29.01	1.87	<0.001	+	
rplJ	**50S ribosomal subunit protein L10**	**28.11**	**2.24**	**0.013**		
rpmD	**50S ribosomal subunit protein L30**	**27.97**	**2.39**	**0.004**	+	
tufA	Protein chain elongation factor EF-Tu	27.53	0.94	0.039	+	
rplD	**50S ribosomal subunit protein L4**	**27.18**	**2.75**	**0.006**		
rplC	**50S ribosomal subunit protein L3**	**27.00**	**2.88**	**0.003**		
ompA	Outer membrane protein A (II*)	26.05	−1.23	0.016	+	+
rplO	**50S ribosomal subunit protein L15**	**25.60**	**2.07**	**0.008**	+	
rpsD	30S ribosomal subunit protein S4	25.49	0.97	0.028	+	
rplF	**50S ribosomal subunit protein L6**	**25.42**	**2.17**	**0.012**	+	
rplL	**50S ribosomal subunit protein L7/L12**	**25.11**	**2.04**	**0.038**		
prlA	Putative ATPase subunit of translocase	24.74	1.98	0.011	+	
rpsJ	**30S ribosomal subunit protein S10**	**24.11**	**2.59**	**<0.001**		
rplW	**50S ribosomal subunit protein L23**	**23.92**	**2.49**	**0.018**		
rpsM	30S ribosomal subunit protein S13	23.91	1.04	0.029	+	
rpsH	30S ribosomal subunit protein S8	23.27	1.96	0.013	+	
rpsC	**30S ribosomal subunit protein S3**	**22.35**	**2.02**	**0.009**		
gapA	Glyceraldehyde-3-phosphate dehydrogenase A	22.31	0.04	0.178	+	+
fusA	GTP-binding protein chain elongation factor EF-G	21.96	1.76	0.002	+	
rplB	**50S ribosomal subunit protein L2**	**21.83**	**2.30**	**0.007**	+	
rplP	50S ribosomal subunit protein L16	21.09	1.72	0.018		
rplV	50S ribosomal subunit protein L22	20.59	1.71	0.010		
rpoA	RNA polymerase, alpha subunit	20.33	1.28	0.007	+	
ptsH	PTS system protein HPr	18.67	0.53	<0.001		
rpsG	30S ribosomal subunit protein S7	18.45	1.44	0.001	+	
fimI	**Type 1 fimbrial protein of unknown function**	**17.97**	**3.65**	**0.007**		
rpsL	30S ribosomal subunit protein S12	17.71	1.28	0.008	+	
rplN	50S ribosomal subunit protein L14	17.40	1.70	0.006	+	
ompC	Outer membrane protein C (porin)	17.27	−0.84	0.002	+	+
rplK	**50S ribosomal subunit protein L11**	**16.78**	**2.09**	**<0.001**		
c1041	Unknown	16.08	−1.01	0.016		+
rpsR	**30S ribosomal subunit protein S18**	**15.99**	**2.66**	**<0.001**		
rpsB	**30S ribosomal subunit protein S2**	**15.75**	**2.20**	**0.001**		
uxuA	**Mannonate hydrolase**	**15.60**	**4.74**	**0.003**		
rpsA	**30S ribosomal subunit protein S1**	**15.51**	**2.16**	**<0.001**		
c4086	**Hypothetical protein**	**15.50**	**3.57**	**0.017**		
ahpC	Alkyl hydroperoxide reductase, C22 subunit	15.13	0.89	0.005		
rplA	**50S ribosomal subunit protein L1**	**14.91**	**2.74**	**0.020**		
infC	Protein chain initiation factor IF-3	14.46	−0.09	0.408	+	+
c0287	Hypothetical protein	14.46	1.28	0.036		
aceE	Pyruvate dehydrogenase (decarboxylase)	14.14	1.05	0.042		
acpP	Acyl carrier protein	13.85	0.09	0.579		

[a] Fold change refers to growth in vivo relative to growth in LB.
[b] Genes statistically upregulated in vivo at least twofold are in boldface.
[c] A plus sign indicates this gene was also present among the 50 most expressed genes in human urine or LB.

upregulated three- to fivefold. *nanA*, encoding an enzyme involved in capsular sialic acid catabolism, and *wzzE*, encoding a putative transport protein involved in LPS biosynthesis, were also upregulated in vivo.

Antibiotic resistance. Genes that confer antibiotic resistance were found upregulated during bacterial growth in vivo. These include *marAB* (two- to three fold), encoding multiple antibiotic resistance proteins, *yhjX* (fivefold), encoding a putative drug resistance protein, and *emrA* (twofold), encoding a multidrug resistance secretion protein. Microcins are secreted antibiotic peptides that may be used to compete with surrounding bacteria. *mchCDEF*, encoding microcin H47, was upregulated two- to fourfold in the urinary tract.

***E. coli* CFT073 transcriptome as a probe for nutrient levels and conditions within the urinary tract.** *E. coli* senses its environment and modulates gene expression to best utilize available resources. By examining the transcriptome of *E. coli* CFT073 isolated from the urine of infected mice, we established that these bacteria can act as sensitive bioprobes to reveal the composition of this environment.

Oxygen level. *E. coli*, a facultative anaerobe, can adapt to growth in various redox environments. Based on the pattern of gene expression of *E. coli* CFT073, the mouse urinary tract is more oxygen rich than the LB static culture. Many genes indicative of anaerobiosis were downregulated under in vivo conditions. Most interestingly, *frdABCD* (encoding fumarate

FIG. 2. Expression of adhesins in *E. coli* CFT073. The signal intensity, corresponding to the relative expression of a gene, is shown for selected adhesin genes in vivo (growth during UTI) or in vitro (growth in static LB culture). Genes upregulated (encircled plus signs) or downregulated (encircled minus signs) in vivo relative to in vitro are indicated.

reductase), *glpABC* (encoding *sn*-glycerol-3-phosphate dehydrogenase), and *aspA* (encoding aspartase), all Fnr-regulated genes downregulated during growth in the urinary tract, were all found to be upregulated in *Vibrio cholerae* during in vivo growth in the intestinal rabbit ileal loop model (45). *tdcABC* (encoding genes for anaerobic threonine usage), *tdcE* (encoding formate acetyltransferase), and Fnr-regulated genes *ansB* (encoding L-asparaginase II) and *hypC* (affects hydrogenase activity) were also downregulated during growth in the urinary tract. Accordingly, *cyoAB* and *cyoE*, cytochrome *o* genes indicative of aerobic growth, were upregulated twofold in vivo. On the other hand, the *fdnGHI* operon encoding anaerobic formate dehydrogenase-N was upregulated under in vivo conditions, thus implying oxygen limitation. *arcA* and *fnr*, the key regulators of respiration and indicators of oxygenation, remained unchanged between in vivo and LB growth. Thus, bacteria were growing neither strictly anaerobically nor strictly aerobically. The urinary tract is likely a combination of these conditions, as bacteria isolated from urine may have been growing in different niches of the urinary tract with different levels of oxygenation.

Nitrogen limitation. Although nitrogen is abundant in urine (e.g., urea is present at ~0.5 M [11]), it is a limiting resource in the urinary tract for *E. coli*, which typically lacks the urease enzyme required to catalyze the hydrolysis of urea to ammonia and CO_2. Nitrogen limitation induces nitrogen-regulated (Ntr) genes, such as *glnA*, which encodes glutamine synthetase. While growing in the urinary tract, *glnA* was upregulated fourfold. To provide an exogenous nitrogen source, glutamine importers *glnP* and *glnQ* were also upregulated threefold. *gadA* and *gadB* (encoding glutamate decarboxylases), for the conversion of L-glutamate to γ-aminobutyrate, and *ybaS* (encoding a probable glutaminase), for the degradation of glutamine, were downregulated 7- to 10-fold, perhaps as a coordinated response to maximize the amount of ammonia assimilated. These data indicate that *E. coli* CFT073 faces nitrogen limitation in the urinary tract.

Iron limitation. *E. coli* CFT073 faces iron limitation in the urinary tract as indicated by the uniform upregulation of iron acquisition systems as described above.

High osmolarity and osmotic stress. The cytosolic concentration of osmoprotectants is elevated under high osmolarity,


FIG. 3. Expression of iron acquisition systems in *E. coli* CFT073. The signal intensity, corresponding to the relative expression of a gene, is shown for selected iron acquisition systems in vivo (growth during UTI) or in vitro (growth in static LB culture). Genes upregulated (encircled plus signs) in vivo relative to the same genes in vitro are indicated.

TABLE 3. Expression of *E. coli* CFT073 class III genes of motility and chemotaxis

Gene	Function	Fold change[a]	P value
flgL[b]	**Flagellar biosynthesis; hook-filament junction protein**	**−3.19**	**0.054**
flgK	**Flagellar biosynthesis, hook-filament junction protein 1**	**−2.36**	**0.004**
fliD	Flagellar biosynthesis; filament capping protein; enables filament assembly	−1.31	0.018
fliS	Flagellar biosynthesis; repressor of class 3a and 3b operons (RflA activity)	−2.53	0.206
fliT	Flagellar biosynthesis; repressor of class 3a and 3b operons (RflA activity)	−1.04	0.441
fliC	**Flagellar biosynthesis; flagellin, filament structural protein**	**−4.65**	**0.006**
tar	Methyl-accepting chemotaxis protein II, aspartate sensor receptor	−3.88	0.060
cheZ	Chemotactic response; CheY protein phophatase	−3.49	0.107
cheY	Transmits chemoreceptor signals to flagellar motor components	−3.73	0.146
cheB	Response regulator for chemotaxis (CheA sensor); protein methylesterase	−0.89	0.397
cheR	Response regulator for chemotaxis; protein glutamate methyltransferase	−0.35	0.678
cheW	**Positive regulator of CheA protein activity**	**−3.35**	**0.012**
cheA	Sensory transducer kinase between signal receptors and CheB and CheY	−2.03	0.117
motB	Enables flagellar motor rotation	−1.36	0.186
motA	Proton conductor component of motor	−0.14	0.903

[a] Fold change refers to growth in vivo relative to growth in LB.
[b] Genes statistically downregulated in vivo at least two-fold are in boldface.

as measured here with the upregulation of *pro* gene expression of *E. coli* CFT073 in the urinary tract. *proP* and *proVWX*, encoding systems for the transport of osmoprotectants proline and glycine betaine, were upregulated two- to fivefold in vivo.

Carbon utilization and starvation response. *E. coli* CFT073 utilized different sources of carbon depending on whether growth was in vivo or in LB. While in the urinary tract, metabolism shifted so that hexuronates and hexanates could be exploited to support growth. *uxuA* and *uxuB*, encoding mannonate dehydratase and oxidoreductase, and *uxaA* and *uxaB*, encoding altronate hydrolase and oxidoreductase, respectively, were upregulated two- to fivefold. Genes encoding glucitol and fructose uptake and catabolism were upregulated three- to fivefold. The genes encoding the uptake and catabolism of glycerol, *sn*-glycerol-3-phosphate, and trehalose were downregulated three- to sevenfold in vivo. Carbon sources that were used equally during in vivo and LB growth conditions include glucose, mannose, and mannitol. Genes encoding carbon starvation proteins were not consistently up- or downregulated. Thus, *E. coli* CFT073 was not limited for carbon sources during acute infection of the urinary tract.

Conditions unchanged between in vivo and LB growth. Groups of genes that were not differentially expressed between in vivo and LB growth conditions provide insight into the similarity between these environments. There was no measurable change in genes that normally respond to pH, oxidative stress, DNA damage, heat or cold shock, cell density dependence, sulfur availability, or phosphate availability (data not shown).

Verification of microarray. qRT-PCR was used to independently verify the levels of transcript for an example gene, *papA_2*, which was found downregulated during growth in vivo 3.5-fold by microarray analysis. *gapA*, encoding glyceraldehyde 3-phosphate dehydrogenase, was used as the normalizing internal standard. Microarray analysis demonstrated that *gapA* expression remained unchanged between in vivo and in vitro growth, thus confirming the validity of this standard. qRT-PCR analysis demonstrated a greater transcript level sensitivity than microarray analysis, as *papA_2* was downregulated 6.24-fold ± 0.15-fold during growth in vivo relative to growth in LB.

To verify the biological reproducibility of our in vivo mi-croarray analysis, the results presented here were compared to those of an analogous microarray of an *E. coli* CFT073 *dsdA* (D-serine deaminase) mutant isolated from the urine of infected CBA/J mice. The upregulation of specific genes encoding type 1 fimbriae, several iron acquisition systems, capsular polysaccharide, and microcin during the in vivo growth of *E. coli* CFT073 *dsdA* demonstrated the biological reproducibility of our major findings (our unpublished data). Pearson's correlation coefficient (r^2) between wild-type *E. coli* CFT073 grown in vivo and CFT073 *dsdA* grown in vivo was 0.7583. By comparison, the correlation coefficient between wild-type *E. coli* CFT073 grown in vivo and grown in vitro in LB was 0.4059, suggesting that the wild type and *dsdA* mutant have similar overall gene expression patterns when grown in vivo.

Alterations in the transcriptome of *E. coli* CFT073 during growth in human urine. *E. coli* CFT073 grown to mid-exponential phase in filtered human urine partially mimics growth in the urinary tract. The transcriptome of *E. coli* CFT073 grown in vitro in human urine, relative to growth in LB, demonstrated the upregulation of genes encoding two iron acquisition systems (*iuc* and *iro* gene clusters), capsular sialic acid catabolism genes (*nanA* and *nanT*), and a microcin secretion gene (*mchB*). Overall, 54 genes were found upregulated (Table 4 lists the 50 most upregulated) and 88 genes were found downregulated during growth in human urine. Many of the most highly expressed genes in vivo are also among the most highly expressed in human urine, including *ompA*, *ompC*, and many ribosomal protein genes (Table 2). However, in sharp contrast to growth in vivo, *papA_2* (encoding the major P fimbriae subunit), *focA* (encoding the major F1C fimbriae subunit), and *fliC* (encoding flagellin) were highly expressed in human urine (data not shown).

DISCUSSION

This study represents the first quantification of the genome-wide transcriptional profile of the most common human uropathogen, *E. coli*, during colonization of the urinary tract. These measurements, taken with bacteria collected from the urine of infected mice, allow us to assess the conditions in the urinary tract

TABLE 4. Top 50 genes upregulated during in vitro growth in human urine

Gene	Function	Fold change[a]	P value	Also upregulated in vivo[b]
yeiC	Hypothetical sugar kinase YeiC	6.646	0.0022	+
rbsD	High affinity ribose transport protein	4.987	0.0021	
artJ	Arginine-binding periplasmic protein 2 precursor	4.730	0.0195	+
c0336	PTS system, mannitol (cryptic)-specific IIA component	4.721	0.0032	
ompF	Outer membrane protein F precursor	4.686	0.0048	
iucD	Aerobactin protein IucD	4.587	0.0047	+
c0335	Hypothetical protein	4.513	0.0032	+
nanA	N-acetylneuraminate lyase subunit	4.225	0.0374	+
leuC	3-Isopropylmalate dehydratase large subunit	4.180	0.0219	
iroB	Siderophore glucosyltransferase	4.144	0.0138	+
leuB	3-Isopropylmalate dehydrogenase	4.141	0.0232	
dppA	Periplasmic dipeptide transport protein precursor	4.124	0.0131	+
c0088	Hypothetical protein	4.030	0.0377	
uxuA	Mannonate dehydratase	3.967	0.0170	+
c0334	Putative integral membrane protein	3.889	0.0079	
ilvC	Ketol-acid reductoisomerase	3.887	0.0343	
yncE	Hypothetical protein YncE precursor	3.849	0.0225	+
ybiW	Putative formate acetyltransferase 3	3.728	0.0491	
yeaR	Hypothetical protein YeaR	3.709	0.0202	+
argC	N-acetyl-gamma-glutamyl-phosphate reductase	3.682	0.0267	
ilvE	Branched-chain amino acid aminotransferase	3.594	0.0274	+
narK	Nitrite extrusion protein 1	3.568	0.0422	
ybeJ	Glutamate/aspartate periplasmic binding protein precursor	3.370	0.0262	+
argB	Acetylglutamate kinase	3.363	0.0320	
ygbJ	Hypothetical oxidoreductase YgbJ	3.263	0.0257	
nanT	Putative sialic acid transporter	3.194	0.0241	
fdnH	Formate dehydrogenase-N beta subunit	3.155	0.0427	+
galE	UDP-glucose 4-epimerase	3.039	0.0235	
narG	Respiratory nitrate reductase 1 alpha chain	3.014	0.0287	
leuL	Leu operon leader peptide	3.003	0.0167	
fdnI	Formate dehydrogenase-N gamma subunit	2.953	0.0207	+
mglA	Galactoside transport ATP-binding protein	2.925	0.0226	
galK	Galactokinase	2.895	0.0455	
hmpA	Flavohemoprotein (hemoglobin-like protein)	2.843	0.0302	+
iutA	Aerobactin protein IutA	2.796	0.0349	+
serA	D-3-phosphoglycerate dehydrogenase	2.793	0.0444	
ytfE	Hypothetical protein YtfE	2.753	0.0395	+
c3835	Hypothetical protein	2.582	0.0401	
livG	High-affinity branched-chain amino acid transport ATP-binding protein	2.479	0.0493	
ilvH	Acetolactate synthase isozyme III small subunit	2.443	0.0166	
uxaC	Uronate isomerase	2.436	0.0392	
livJ	Leu/Ile/Val-binding protein precursor	2.416	0.0291	
hisJ	Histidine-binding periplasmic protein precursor	2.385	0.0117	
yjiY	Hypothetical protein YjiY	2.278	0.0479	
mchB	Microcin H47 secretion protein	2.228	0.0462	
asnB	Asparagine synthetase B (glutamine hydrolyzing)	2.204	0.0395	
cyoD	Cytochrome o ubiquinol oxidase protein	2.184	0.0458	
narI	Respiratory nitrate reductase 1 gamma chain	2.176	0.0278	
cyoE	Protoheme IX farnesyltransferase	2.176	0.0370	+
argE	Acetylornithine deacetylase	2.088	0.0199	

[a] Fold change refers to growth in human urine relative to growth in LB.
[b] A plus sign indicates this gene was also upregulated during growth in vivo relative to growth in LB.

as seen from the point of view of the pathogen. We describe the first use of microarray technology, based on the sequence of a urinary tract pathogen, to globally examine the induction of specific virulence genes and the coordinate regulation among different virulence and metabolic gene clusters during a UTI. Expression patterns were verified by an example gene by qRT-PCR and by a comparison of major findings to those of in vivo microarray analysis of an *E. coli* CFT073 *dsdA* mutant. In addition, this microarray analysis represents the first assessment of the transcriptome of any *E. coli* pathotype in vivo.

The transcriptional analysis of *E. coli* CFT073 during colo-

nization of the murine urinary tract was feasible because the urinary tract is naturally sterile and because the amount of host nucleic acid contamination from exfoliated epithelial cells (12, 30) was insignificant. This allowed us to collect the urine from experimentally infected mice and directly extract CFT073-specific RNA. We experienced limited complications in isolating ample RNA, provided a sufficient volume of urine was collected from infected animals. Previous studies demonstrated that individual CBA/J mice are consistently and relatively uniformly infected with *E. coli* CFT073 (13). Additionally, urine from 20 mice individually cultured at the conclusion of these

microarray experiments demonstrated that all mice remained infected (data not shown). Urine was sampled and pooled over a range of time (1 to 10 days) from a large collection of infected mice ($n = 40$). Bacteria expelled in the urine likely represent an appropriate sample of the bacteria that had recently infected the kidneys, ureters, bladder, and urethra. Therefore, we assume that the RNA used for this in vivo microarray analysis provides a representation of the responses of a uropathogen to a summation of these environmental situations encountered in the urinary tract.

Urine was not collected within the first 24 h of the experimental UTI. We desired to exclude noncolonizing bacteria that were present in the inoculum that may have washed out following transurethral challenge. Instead we focused on a bacterial population that had colonized and adapted to the murine urinary tract. Admittedly, this analysis likely excluded the transient transcription of genes encoding colonization factors and other virulence determinants required for the transition from the in vitro LB culture to growth in the urinary tract. Additionally, any gene transiently expressed during the ongoing urine collection would be diluted out in the process of pooling urine samples. Thus, our analysis emphasizes genes that are efficiently expressed throughout space and time during UTI.

Microarray data presented here are internally consistent and compatible with previous studies. There is coordinated regulation of genes within an operon, and transcript levels reflect the expected abundance. For example, the entire *fimAICDFGH* gene cluster of type 1 fimbriae is upregulated in vivo compared to that in LB growth (Fig. 2), and as expected there is significantly more *fimA* (major structural subunit gene) transcript than *fimI*, more *fimI* than *fimC*, more *fimC* than *fimD*, and more *fimD* than *fimF*. This is consistent with the prediction of a transcript-stabilizing stem-loop structure at the end of *fimA* (34) as well as in vitro expression studies of other chaperone-usher fimbrial gene clusters (2). Genes within iron acquisition operons are also uniformly upregulated (Fig. 3), consistent with a previous study of *E. coli* CFT073 that observed the induction of three siderophore systems during murine peritonitis (35).

We affirm the importance of several known virulence genes by reporting the upregulation of these genes in vivo, such as those encoding type 1 fimbriae, siderophores, capsule, drug resistance, and microcin. We have also identified 13 new candidate virulence genes, encoding hypothetical proteins, which were upregulated during in vivo growth and were simultaneously not found in the nonpathogenic *E. coli* K-12 strain. Additionally, these analyses provide valuable information on the expression of surface proteins in vivo for the purpose of vaccine-directed research.

Several other microarray analyses found that genes encoding ribosomal proteins were highly expressed when cells were exponentially growing in rich media (5, 41, 45). This suggests that the high level of in vivo expression of genes involved in translation indicates a rapid rate of exponential growth of pyelonephritogenic *E. coli* CFT073 in the urinary tract. This is somewhat surprising, given that urine is an incomplete and relatively poor growth medium in vitro (19, 38). Although bacteria may acquire some nutrients via contact with the urinary tract epithelium, our experiments indicate that nitrogen and iron remain limiting. In addition, bacteria are expending additional energy responding to osmotic stress and producing virulence

and metabolic factors specific for survival in the host. Despite these specific nutrient deprivations and energy expenditures, rapid growth is sustained in the urinary tract. This is in contrast to observations of *V. cholerae* during growth in the intestine, where fewer genes for protein synthesis tended to be found among the 300 most highly expressed genes compared to that of growth in LB (45).

Microarray analysis demonstrates a strikingly high level of type 1 fimbrial expression during growth in vivo, as *fimA* expression was the fourth highest gene expressed overall. In addition, type 1 fimbrial genes are highly upregulated compared to that of growth in LB. These data support the findings of studies using signature-tagged mutagenesis and phase-locked mutants (3, 13). Type 1 fimbrial expression in vivo contrasts sharply with the near lack of expression of the 11 other fimbrial types previously demonstrated (4, 21) or predicted by the *E. coli* CFT073 genome (42). Coordinate regulation among fimbrial operons has been described previously and may provide an explanation for this observation (17, 44). P fimbriae, argued as being virulence factors during UTI (43), are found downregulated here in vivo despite the presence of P-fimbrial Gal-Gal receptors in mice (22, 32). Our microarray experiments suggest that a better way to study the importance of other adherence factors may be use of a Fim-deficient UPEC mutant.

The signals necessary for transcriptional alterations in UPEC during transition from growth in the intestine to growth in the urinary tract remain undisclosed. However, this microarray analysis of bacteria responding to the urinary tract can be compared to the two other true in vivo microarray analyses, where *V. cholerae* was isolated from rice-water stools of infected patients (5, 27). By using bacteria as bioprobes for their respective environments, differences in these niches are revealed by patterns of bacterial gene expression. For example, the urinary tract is nitrogen and iron limiting for *E. coli*, of moderate oxygenation, and of higher osmolarity and pH than the anaerobic, nitrogen-rich gastrointestinal tract.

Differences in gene expression between growth in vivo and growth in vitro in human urine may be partially due to species-specific differences in urine composition. This use of human urine as a growth medium thus examines the important relationship between in vivo murine studies and human infection. This work also suggests that in vitro growth of UPEC in human urine, rather than in LB, is a useful tool to more closely imitate growth conditions encountered during UTI. The upregulation of important virulence factors, including iron acquisition systems, capsule, and microcin, was observed. However, the most highly expressed virulence factor during UTI, type 1 fimbriae, was not induced in urine. The examination of gene expression in vivo by using the experimental murine model of ascending UTI thus remains essential.

with a subcontract to the Application Development Center at the University of Wisconsin—Madison.

REFERENCES

1. **Allen, T. E., and B. O. Palsson.** 2003. Sequence-based analysis of metabolic demands for protein synthesis in prokaryotes. J. Theor. Biol. **220:**1–18.
2. **Baga, M., M. Goransson, S. Normark, and B. E. Uhlin.** 1985. Transcriptional activation of a pap pilus virulence operon from uropathogenic *Escherichia coli*. EMBO J. **4:**3887–3893.
3. **Bahrani-Mougeot, F. K., E. L. Buckles, C. V. Lockatell, J. R. Hebel, D. E. Johnson, C. M. Tang, and M. S. Donnenberg.** 2002. Type 1 fimbriae and extracellular polysaccharides are preeminent uropathogenic *Escherichia coli* virulence determinants in the murine urinary tract. Mol. Microbiol. **45:**1079–1093.
4. **Bahrani-Mougeot, F. K., S. Pancholi, M. Daoust, and M. S. Donnenberg.** 2001. Identification of putative urovirulence genes by subtractive cloning. J. Infect. Dis. **183**(Suppl. 1):S21–S23.
5. **Bina, J., J. Zhu, M. Dziejman, S. Faruque, S. Calderwood, and J. Mekalanos.** 2003. ToxR regulon of *Vibrio cholerae* and its expression in vibrios shed by cholera patients. Proc. Natl. Acad. Sci. USA **100:**2801–2806.
6. **Bolstad, B. M., R. A. Irizarry, M. Astrand, and T. P. Speed.** 2003. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics **19:**185–193.
7. **Connell, I., W. Agace, P. Klemm, M. Schembri, S. Marild, and C. Svanborg.** 1996. Type 1 fimbrial expression enhances *Escherichia coli* virulence for the urinary tract. Proc. Natl. Acad. Sci. USA **93:**9827–9832.
8. **Culham, D. E., C. Dalgado, C. L. Gyles, D. Mamelak, S. MacLellan, and J. M. Wood.** 1998. Osmoregulatory transporter ProP influences colonization of the urinary tract by *Escherichia coli*. Microbiology **144:**91–102.
9. **Falkow, S.** 1988. Molecular Koch's postulates applied to microbial pathogenicity. Rev. Infect. Dis. **10**(Suppl. 2):S274—S276.
10. **Green, C. P., and V. L. Thomas.** 1981. Hemagglutination of human type O erythrocytes, hemolysin production, and serogrouping of *Escherichia coli* isolates from patients with acute pyelonephritis, cystitis, and asymptomatic bacteriuria. Infect. Immun. **31:**309–315.
11. **Griffith, D. P., D. M. Musher, and C. Itin.** 1976. Urease. The primary cause of infection-induced urinary stones. Investig. Urol. **13:**346–350.
12. **Gunther, N. W. I., V. Lockatell, D. E. Johnson, and H. L. Mobley.** 2001. In vivo dynamics of type 1 fimbria regulation in uropathogenic *Escherichia coli* during experimental urinary tract infection. Infect. Immun. **69:**2838–2846.
13. **Gunther, N. W. I., J. A. Snyder, V. Lockatell, I. Blomfield, D. E. Johnson, and H. L. Mobley.** 2002. Assessment of virulence of uropathogenic *Escherichia coli* type 1 fimbrial mutants in which the invertible element is phase-locked on or off. Infect. Immun. **70:**3344–3354.
14. **Guyer, D. M., S. Radulovic, F. E. Jones, and H. L. Mobley.** 2002. Sat, the secreted autotransporter toxin of uropathogenic *Escherichia coli*, is a vacuolating cytotoxin for bladder and kidney epithelial cells. Infect. Immun. **70:**4539–4546.
15. **Hagberg, L., I. Engberg, R. Freter, J. Lam, S. Olling, and C. Svanborg Eden.** 1983. Ascending, unobstructed urinary tract infection in mice caused by pyelonephritogenic *Escherichia coli* of human origin. Infect. Immun. **40:**273–283.
16. **Herrmann, B., and L. G. Burman.** 1985. Pathogenesis of *Escherichia coli* cystitis and pyelonephritis: apparent lack of significance of bacterial motility and chemotaxis towards human urine. Infection **13:**4–7.
17. **Holden, N. J., B. E. Uhlin, and D. L. Gally.** 2001. PapB paralogues and their effect on the phase variation of type 1 fimbriae in *Escherichia coli*. Mol. Microbiol. **42:**319–330.
18. **Horwitz, M. A., and S. C. Silverstein.** 1980. Influence of the *Escherichia coli* capsule on complement fixation and on phagocytosis and killing by human phagocytes. J. Clin. Investig. **65:**82–94.
19. **Hull, R. A., and S. I. Hull.** 1997. Nutritional requirements for growth of uropathogenic *Escherichia coli* in human urine. Infect. Immun. **65:**1960–1961.
20. **Irizarry, R. A., B. Hobbs, F. Collin, Y. D. Beazer-Barclay, K. J. Antonellis, U. Scherf, and T. P. Speed.** 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics **4:**249–264.
21. **Johnson, D. E., C. V. Lockatell, R. G. Russell, J. R. Hebel, M. D. Island, A. Stapleton, W. E. Stamm, and J. W. Warren.** 1998. Comparison of *Escherichia coli* strains recovered from human cystitis and pyelonephritis infections in transurethrally challenged mice. Infect. Immun. **66:**3059–3065.
22. **Johnson, J. R., T. Berggren, D. S. Newburg, R. H. McCluer, and J. C. Manivel.** 1992. Detailed histopathological examination contributes to the assessment of *Escherichia coli* urovirulence. J. Urol. **147:**1160–1166.
23. **Johnson, J. R., and A. L. Stell.** 2000. Extended virulence genotypes of *Escherichia coli* strains from patients with urosepsis in relation to phylogeny and host compromise. J. Infect. Dis. **181:**261–272.
24. **Johnson, J. R., A. L. Stell, P. Delavari, A. C. Murray, M. Kuskowski, and W.**
Gaastra. 2001. Phylogenetic and pathotypic similarities between *Escherichia coli* isolates from urinary tract infections in dogs and extraintestinal infections in humans. J. Infect. Dis. **183:**897–906.
25. **Livak, K. J., and T. D. Schmittgen.** 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods **25:**402–408.
26. **Manges, A. R., J. R. Johnson, B. Foxman, T. T. O'Bryan, K. E. Fullerton, and L. W. Riley.** 2001. Widespread distribution of urinary tract infections caused by a multidrug-resistant *Escherichia coli* clonal group. N. Engl. J. Med. **345:**1007–1013.
27. **Merrell, D. S., S. M. Butler, F. Qadri, N. A. Dolganov, A. Alam, M. B. Cohen, S. B. Calderwood, G. K. Schoolnik, and A. Camilli.** 2002. Host-induced epidemic spread of the cholera bacterium. Nature **417:**642–645.
28. **Mobley, H. L., D. M. Green, A. L. Trifillis, D. E. Johnson, G. R. Chippendale, C. V. Lockatell, B. D. Jones, and J. W. Warren.** 1990. Pyelonephritogenic *Escherichia coli* and killing of cultured human renal proximal tubular epithelial cells: role of hemolysin in some strains. Infect. Immun. **58:**1281–1289.
29. **Mobley, H. L., M. D. Island, and G. Massad.** 1994. Virulence determinants of uropathogenic *Escherichia coli* and *Proteus mirabilis*. Kidney Int. Suppl. **47:**S129–S136.
30. **Mulvey, M. A., Y. S. Lopez-Boado, C. L. Wilson, R. Roth, W. C. Parks, J. Heuser, and S. J. Hultgren.** 1998. Induction and evasion of host defenses by type 1-piliated uropathogenic *Escherichia coli*. Science **282:**1494–1497.
31. **Neidhardt, F. C., and R. Curtiss.** 1996. *Escherichia coli* and *Salmonella*: cellular and molecular biology, 2nd ed. ASM Press, Washington, D.C.
32. **O'Hanley, P., D. Lark, S. Falkow, and G. Schoolnik.** 1985. Molecular basis of *Escherichia coli* colonization of the upper urinary tract in BALB/c mice. Gal-Gal pili immunization prevents *Escherichia coli* pyelonephritis in the BALB/c mouse model of human pyelonephritis. J. Clin. Investig. **75:**347–360.
33. **Old, D. C., and J. P. Duguid.** 1970. Selective outgrowth of fimbriate bacteria in static liquid medium. J. Bacteriol. **103:**447–456.
34. **Olsen, P. B., and P. Klemm.** 1994. Localization of promoters in the *fim* gene cluster and the effect of H-NS on the transcription of *fimB* and *fimE*. FEMS Microbiol. Lett. **116:**95–100.
35. **Redford, P., P. L. Roesch, and R. A. Welch.** 2003. DegS is necessary for virulence and is among extraintestinal *Escherichia coli* genes induced in murine peritonitis. Infect. Immun. **71:**3088–3096.
36. **Rippere-Lampe, K. E., A. D. O'Brien, R. Conran, and H. A. Lockman.** 2001. Mutation of the gene encoding cytotoxic necrotizing factor type 1 (cnf_1) attenuates the virulence of uropathogenic *Escherichia coli*. Infect. Immun. **69:**3954–3964.
37. **Rosenow, C., R. M. Saxena, M. Durst, and T. R. Gingeras.** 2001. Prokaryotic RNA preparation methods useful for high density array analysis: comparison of two approaches. Nucleic Acids Res. **29:**E112.
38. **Russo, T. A., S. T. Jodush, J. J. Brown, and J. R. Johnson.** 1996. Identification of two previously unrecognized genes (*guaA* and *argC*) important for uropathogenesis. Mol. Microbiol. **22:**217–229.
39. **Schappert, S. M.** 1999. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States Series 13, no. 143. National Center for Health Statistics, Centers for Disease Control and Prevention, Atlanta, Ga.
40. **Torres, A. G., P. Redford, R. A. Welch, and S. M. Payne.** 2001. TonB-dependent systems of uropathogenic *Escherichia coli*: aerobactin and heme transport and TonB are required for virulence in the mouse. Infect. Immun. **69:**6179–6185.
41. **Wei, Y., J. M. Lee, C. Richmond, F. R. Blattner, J. A. Rafalski, and R. A. LaRossa.** 2001. High-density microarray-mediated gene expression profiling of *Escherichia coli*. J. Bacteriol. **183:**545–556.
42. **Welch, R. A., V. Burland, G. Plunkett III, P. Redford, P. Roesch, D. Rasko, E. L. Buckles, S. R. Liou, A. Boutin, J. Hackett, D. Stroud, G. F. Mayhew, D. J. Rose, S. Zhou, D. C. Schwartz, N. T. Perna, H. L. Mobley, M. S. Donnenberg, and F. R. Blattner.** 2002. Extensive mosaic structure revealed by the complete genome sequence of uropathogenic *Escherichia coli*. Proc. Natl. Acad. Sci. USA **99:**17020–17024.
43. **Wullt, B., G. Bergsten, M. Samuelsson, N. Gebretsadik, R. Hull, and C. Svanborg.** 2001. The role of P fimbriae for colonization and host response induction in the human urinary tract. J. Infect. Dis. **183**(Suppl. 1):S43–S46.
44. **Xia, Y., D. Gally, K. Forsman-Semb, and B. E. Uhlin.** 2000. Regulatory cross-talk between adhesin operons in *Escherichia coli*: inhibition of type 1 fimbriae expression by the PapB protein. EMBO J. **19:**1450–1457.
45. **Xu, Q., M. Dziejman, and J. J. Mekalanos.** 2003. Determination of the transcriptome of *Vibrio cholerae* during intraintestinal growth and midexponential phase in vitro. Proc. Natl. Acad. Sci. USA **100:**1286–1291.
46. **Zielske, J. V., K. N. Lohr, R. H. Brook, and G. A. Goldberg.** 1981. Conceptualization and measurement of physiologic health for adults. Urinary tract infection, vol. 16. R-2262/16-HHS. The Rand Corporation, Washington, D.C.

Editor: A. D. O'Brien